US Section 301 probe: There was a time when China could expand manufacturing with little external resistance. That tolerance has narrowed. When India attempts expansion today, it faces scrutiny. The United States has initiated a Section 301 investigation into alleged “structural excess capacity” in India. The claim is familiar: producers are creating surplus and dumping exports at low prices. Indian industry has responded in unusual coordination.
This is not a routine trade dispute. It is a disagreement over how India’s industrial expansion is being read. The government is pushing manufacturing to raise growth and income levels. That is explicit policy. Instruments such as production-linked incentive schemes and calibrated tariff structures are part of this effort. The US interpretation is that such policies can create excess capacity and distort markets.
READ | India’s exports resilience masks narrow, fragile gains
Industry rejects this. The argument is simple: production is demand-led. Penalising it would misread both intent and data.
Section 301, under the Trade Act of 1974, is designed to address unfair trade practices. It is a unilateral instrument, operating outside the dispute settlement system of the World Trade Organisation. Indian submissions to the Office of the United States Trade Representative (USTR) stress a key distinction: India is not following an export-surplus model.
Domestic demand, not export dumping
Textiles illustrate the point. The sector is valued at about $182 billion. Roughly four-fifths is domestic consumption. Exports are about $37 billion and spread across markets. The US is only one destination.
India’s share in US apparel imports is around 6%. That is too small to influence prices or displace domestic producers. Exports are largely order-driven. They respond to buyer demand, not surplus disposal. The same pattern holds in other sectors.
Automotive components expand in response to domestic demand and global sourcing decisions by OEMs. Investment is private-led rather than driven by state-directed production targets. Export shares to the US remain modest.
READ | India-US trade deal remains stuck in limbo
Pharmaceuticals operate on a different axis. India supplies low-cost generics at scale. Industry submissions note the absence of policies designed to create excess capacity. The sector stabilises global supply rather than distorting it.
Solar manufacturing does not face surplus. It faces shortage. Domestic capacity is insufficient for India’s renewable targets. Steel, often central to overcapacity debates, shows a similar divergence. Capacity additions track infrastructure demand and urbanisation. Per capita steel consumption in India remains below global averages. The headroom is domestic. Exports to the US are already constrained by Section 232 tariffs.
Market share and the China effect
India’s rising presence in US imports coincides with a decline in Chinese supply in several segments. This is substitution, not surplus creation.
The distinction matters. China’s model relied on large-scale state-directed capacity, high export intensity, and persistent current account surpluses. India’s manufacturing expansion is led by private investment and domestic absorption. The shift in US sourcing reflects diversification, not a new source of systemic overcapacity.
READ | Why domestic value addition is the real test of PLI success
Injury test and missing evidence
Section 301 actions require more than identifying policies. They require evidence of injury to US economic interests. Industry bodies argue that such evidence is absent. India’s share in US manufacturing imports remains modest. There is no clear displacement of domestic production.
The counter-argument is forward-looking: that policy-supported capacity today could translate into export surges later. That concern, however, rests on assumptions about scale and export dependence that current data does not support.
US Section 301 probe: Timing and policy friction
The timing of the probe is awkward. Both countries are attempting to deepen cooperation in supply chains and critical technologies, even as the United States expands its own industrial policy through measures such as the CHIPS and Science Act and clean energy subsidies.
Investigations of this kind introduce friction without resolving the underlying issue: how to distinguish legitimate industrialisation from distortion.
For India, the task is narrower. It must state its industrial strategy in measurable terms and defend it with data. The burden of proving injury, however, lies with those alleging it.